newsfilter
← Earnings
Earnings Releases·

Apnimed — Third Quarter 2026 Earnings Summary

Apnimed reported a net loss of $29.5 million for the third quarter ended September 30, 2026, driven by increased general and administrative expenses related to commercial launch preparations. The company holds $351.8 million in cash and cash equivalents, which is expected to fund operations and a potential U.S. launch into the second quarter of 2028. Its New Drug Application for AD109, proposed as Oxnimbi, remains under FDA review with a PDUFA goal date of February 28, 2027. Additionally, Apnimed presented five abstracts at the CHEST 2026 Annual Meeting, including two late-breakers highlighting Phase 3 clinical data for the drug.

Company
APNIMED INC
Sector
Healthcare
Industry
Biotechnology